Document:

Exhibit
10.1

 

Execution
Copy

 

H-CYTE,
INC.

 

SECURED
CONVERTIBLE NOTE PURCHASE AGREEMENT

 

as
of April 1, 2021

 

    	 

    	 

    

 

TABLE
OF CONTENTS

 

	 	 	Page
	1.	Purchase
    and Sale of Convertible Notes	1
	 	1.1	Sale
    and Issuance of Convertible Notes	1
	 	1.2	Use
    of Proceeds	2
	 	1.3	Defined
    Terms Used in this Agreement	2
	2.	Representations
    and Warranties of the Company	6
	 	2.1	Organization,
    Good Standing, Corporate Power and Qualification	6
	 	2.2	Subsidiaries	6
	 	2.3	Authorization	6
	 	2.4	Valid
    Issuance	6
	 	2.5	Governmental
    Consents and Filings; Compliance with Law and Other Instruments	7
	 	2.6	Financial
    Condition	7
	 	2.7	Title
    to Assets	8
	 	2.8	SEC
    Reports	8
	 	2.9	Certain
    Fees	8
	 	2.10	Private
    Placement	8
	 	2.11	Investment
    Company	9
	 	2.12	Listing
    and Maintenance Requirements	9
	 	2.13	No
    Integrated Offering	9
	 	2.14	Tax
    Status	9
	 	2.15	No
    General Solicitation	9
	 	2.16	Foreign
    Corrupt Practices	9
	 	2.17	No
    Disagreements with Accountants and Lawyers; Outstanding SEC Comments	10
	 	2.18	Acknowledgment
    Regarding Purchasers’ Purchase of Securities	10
	 	2.19	Disqualification	10
	 	2.20	Acknowledgment
    Regarding Each Purchaser’s Trading Activities	10
	 	2.21	Regulation
    M Compliance	11
	 	2.22	Insurance	11
	 	2.23	Office
    of Foreign Assets Control	11
	 	2.24	Money
    Laundering	11
	 	2.25	Takeover
    Protections	12
	 	2.26	Promotional
    Stock Activities	12
	 	2.27	Disclosure	12

 

    	i

    	 

    

 

TABLE
OF CONTENTS

(continued) 

 

	 	 	Page
	3.	Representations
    and Warranties of the Purchasers	12
	 	3.1	Authorization	12
	 	3.2	Purchase
    Entirely for Own Account	12
	 	3.3	Restricted
    Securities	13
	 	3.4	No
    Public Market	13
	 	3.5	Legends	13
	 	3.6	Accredited
    Investor	14
	 	3.7	U.S.
    Investors	14
	 	3.8	No
    General Solicitation	14
	 	3.9	Residence	14
	 	3.10	Exculpation
    Among Purchasers	14
	4.	Other
    Agreements of the Parties	14
	 	4.1	Acknowledgment
    of Dilution	14
	 	4.2	Furnishing
    of Information	14
	 	4.3	Integration	15
	 	4.4	Securities
    Laws Disclosure; Publicity	15
	 	4.5	Shareholder
    Rights Plan	15
	 	4.6	Non-Public
    Information	16
	 	4.7	Indemnification
    of Purchasers	16
	 	4.8	Reservation
    and Listing of Securities	17
	 	4.9	Form
    D; Blue Sky Filings	17
	 	4.10	Transfer
    Agent	18
	 	4.11	Corporate
    Existence	18
	 	4.12	Equal
    Treatment of Purchasers	18
	5.	Conditions
    to the Purchasers’ Obligations at each Closing	18
	 	5.1	Representations
    and Warranties True and Correct	18
	 	5.2	Qualifications	18
	 	5.3	Exemption
    from Registration Requirements	18
	 	5.4	Consents	18
	 	5.5	No
    Material Adverse Effect	18
	6.	Conditions
    to the Company’s Obligations at each Closing	19
	 	6.1	Representations
    and Warranties	19
	 	6.2	Qualifications	19

 

    	ii

    	 

    

 

TABLE
OF CONTENTS

(continued) 

 

	 	 	Page
	7.	Agent	19
	 	7.1	Appointment
    of Agent	19
	 	7.2	Delegation
    of Duties	19
	 	7.3	Exculpatory
    Provisions	19
	 	7.4	Reliance
    by the Agent	19
	 	7.5	Non-Reliance
    on Agent	20
	 	7.6	Indemnification	20
	 	7.7	Agent
    in its Individual Capacity	20
	 	7.8	No
    Action by Other Purchasers	20
	8.	Miscellaneous	21
	 	8.1	Survival
    of Warranties	21
	 	8.2	Communications	21
	 	8.3	Transfer;
    Successors and Assigns	21
	 	8.4	Governing
    Law	21
	 	8.5	Dispute
    Resolution	21
	 	8.6	Counterparts;
    Facsimile Signatures	21
	 	8.7	Titles
    and Subtitles	22
	 	8.8	Notices	22
	 	8.9	No
    Finder’s Fees	22
	 	8.10	Fees
    and Expenses	22
	 	8.11	Attorneys’
    Fees	22
	 	8.12	Amendments
    and Waivers	22
	 	8.13	Severability	23
	 	8.14	No
    Waiver; Remedies Cumulative	23
	 	8.15	Entire
    Agreement	23
	 	8.16	Legal
    Counsel	23
	 	8.17	Acknowledgment	23
	 	8.18	Termination
    of Existing Investor Documents	23

 

	 	 
	Exhibit
    A	Form
    of Note
	Exhibit
    B	Form
    of Security Agreement
	Exhibit
    C	Form
    of Subsidiary Guaranty
	Exhibit
    D	Form
    of IP Security Agreement

 

    	iii

    	 

    

 

SECURED
CONVERTIBLE NOTE PURCHASE AGREEMENT

 

This
Secured Convertible Note Purchase Agreement (this “Agreement”) is entered into as of April 1, 2021 (the “Effective
Date”), by and among H-Cyte, Inc., a Nevada corporation (the “Company”), FWHC Bridge, LLC, a Delaware
limited liability company (the “Lead Purchaser”) and any other Purchaser delivering a counterpart signature
page to this Agreement.

 

The
parties agree as follows:

 

1.
Purchase and Sale of Convertible Notes.

 

1.1.
Sale and Issuance of Convertible Notes.

 

(a)
The initial purchase and sale of the Notes contemplated by this Section 1.1(a) (the “Initial Closing”)
will take place remotely via the exchange of documents and signatures on the date of this Agreement. Subject to the terms and
conditions of this Agreement, at the Initial Closing, the Lead Purchaser and the other Purchasers party hereto on the Effective
Date (collectively with the Lead Purchaser, the “Initial Purchasers”) will each advance to the Company an amount
equal to the “Principal Amount of Note” set forth opposite such Initial Purchaser’s name on Schedule
I to this Agreement and the Company will sell and issue to each Initial Purchaser a secured convertible promissory note, in
the form attached as Exhibit A to this Agreement in the original principal amount of such Initial Purchaser’s “Principal
Amount of Note”. The secured convertible promissory notes issued at the Initial Closing are referred to herein as the “Initial
Notes”.

 

(b)
Following the Initial Closing, the Company may, subject to the approval of the Lead Purchaser, offer, issue and sell, on the same
price, terms and conditions as those contained in this Agreement, at one or more subsequent closings (each, an “Additional
Closing”), secured convertible promissory notes, each in the form attached as Exhibit A to this Agreement (the
“Additional Notes” and together with the Initial Notes, the “Notes”) to the Lead Purchaser
and/or one or more additional investors who executes a counterpart signature page to this Agreement (the “Additional
Purchasers” and together with the Lead Purchaser, the “Purchasers”). Upon any Additional Closing,
Schedule I to this Agreement shall be updated to reflect any Additional Notes purchased at such Additional Closing. The
principal amount of each Note set forth on Schedule I is referred to herein as the respective Purchaser’s “Principal
Amount”.

 

(c)
Subject to the terms and conditions of this Agreement, at each Closing, the Company shall deliver to each applicable Purchaser
in addition to their Note(s): (i) the Security Agreement substantially in the form attached hereto as Exhibit B, duly executed
by the Company (the “Security Agreement”), (ii) the Absolute Guaranty of Payment and Performance in the form
attached hereto as Exhibit C (the “Subsidiary Guaranty”), duly executed by each Subsidiary of the Company,
(iii) and the Intellectual Property Security Agreement in the form attached hereto as Exhibit D, duly executed by the Company
(the “IP Security Agreement”).

 

(d)
Each purchase of Securities by a Purchaser is a separate transaction from each other purchase of Securities by any other Purchaser.
No Purchaser shall have any obligation to purchase any Securities or otherwise provide any additional funding to the Company other
than as set forth on Schedule I and in any event on the terms and subject to the conditions in this Agreement. Any and
all obligations of the Purchasers under the Transaction Documents are several and not joint and several; no Purchaser shall be
liable for the failure of any other Purchaser to purchase any Securities in accordance with this Section 1.1, for any breach
of representation or warranty by any other Purchaser, or for any other act or omission by any other Purchaser.

 

    	 

    	 

    

 

1.2.
Use of Proceeds. In accordance with the directions of the Board, the Company will use the proceeds from the sale of the
Notes for funding the Company’s payroll and other general corporate purposes and shall not use such proceeds: (a) for the
satisfaction of any portion of the Company’s debt, (b) for the redemption of any Common Stock or Common Stock Equivalents,
(c) for the settlement of any outstanding litigation, or (d) in violation of FCPA or OFAC regulations.

 

1.3.
Defined Terms Used in this Agreement. The following terms used in this Agreement have the meanings set forth or referenced
below.

 

“Acquiring
Person” has the meaning set forth in Section 4.5 of this Agreement.

 

“Action”
means any action, claim, suit, inquiry, notice of violation, proceeding or investigation before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign), whether commenced or threatened.

 

“Additional
Closing” has the meaning set forth in Section 1.1(b) of this Agreement.

 

“Additional
Notes” has the meaning set forth in Section 1.1(b) of this Agreement.

 

“Additional
Purchaser” and “Additional Purchasers” has the meaning set forth in Section 1.1(b) of this
Agreement.

 

“Affiliate”
means, with respect to any specified Person, any other Person who or which, directly or indirectly, Controls, is Controlled by,
or is under common Control with such specified Person, including, without limitation, any general partner, officer, director,
managing member or manager of such Person or any venture capital fund or family office now or hereafter existing that is Controlled
by one or more general partners, managing members or managers of, or shares the same management company with, such Person.

 

“Agreement”
has the meaning set forth in the first paragraph of this Agreement.

 

“Applicable
Law” means any domestic or foreign, federal, state or local statute, law, ordinance, policy, guidance, rule, administrative
interpretation, regulation, order, writ, injunction, directive, judgment, decree or other legal requirement, of any governmental
authority applicable to the Company or any of its properties, assets, operations, officers, directors, employees, consultants
or agents.

 

“Board”
means the Board of Directors of the Company.

 

“Business
Day” means any day other than a Saturday, Sunday or a day on which banks are required or permitted to be closed in Tampa,
Florida.

 

    	2

    	 

    

 

“Certificate”
means the Second Amended and Restated Articles of Incorporation of the Company, filed with the Secretary of State of Nevada on
July 30, 2020.

 

“Closing”
means the Initial Closing and each Additional Closing (if any).

 

“Code”
means the Internal Revenue Code of 1986, as amended.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means shares of the Company’s common stock, par value $0.001 per share.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, the Notes, the Conversion Shares, any debt, preferred stock,
rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive Common Stock.

 

“Company”
has the meaning set forth in the first paragraph of this Agreement.

 

“Control”
as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

 

“Conversion
Shares” means, collectively, the shares of the Company’s preferred stock issuable upon conversion of the Notes
and the shares of Common Stock issuable upon conversion of such shares of preferred stock.

 

“Disqualifying
Event” has the meaning set forth in Section 2.19 of this Agreement.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Existing
Investor Documents” means, collectively, the Investors’ Rights Agreement, the Right of First Refusal and Co-Sale
Agreement and the Voting Agreement.

 

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

 

“Financial
Statements” has the meaning set forth in Section 2.6 of this Agreement.

 

“Indebtedness”
means, with respect to any Person, without duplication, such Person’s (a) obligations for borrowed money, (b) obligations
representing the deferred purchase price of property or services (other than accounts payable arising in the ordinary course of
such Person’s business payable on terms customary in the trade and not outstanding more than 90 days past the date of invoice),
(c) obligations, whether or not assumed, secured by Liens or payable out of the proceeds or production from property now or hereafter
owned or acquired by such Person (but the amount of such Indebtedness shall not exceed the lesser of such Indebtedness or the
value of the property subject to such Lien), (d) obligations which are evidenced by notes, acceptances, or other debt instruments,
(e) obligations of such Person to purchase securities or other property arising out of or in connection with the sale of the same
or substantially similar securities or property, (f) obligations under capitalized leases and obligations created or arising under
any conditional sale or other title retention agreement, (g) contingent obligations, (h) obligations under or relating to hedging
or swap instruments, (i) off-balance sheet liabilities, (j) obligations under sale and leaseback transactions, and (k) the aggregate
undrawn face amount of all letters of credit issued for the account and/or upon the application of such Person together with all
unreimbursed drawings with respect thereto.

 

    	3

    	 

    

 

“Initial
Closing” has the meaning set forth in Section 1.1(a) of this Agreement.

 

“Initial
Note” has the meaning set forth in Section 1.1(b) of this Agreement.

 

“Initial
Purchasers” has the meaning set forth in Section 1.1(b) of this Agreement.

 

“Investors’
Rights Agreement” means the Investors’ Rights Agreement, dated as of November 15, 2019, among the Company and
certain stockholders of the Company, as it may be amended and/or restated.

 

“IP
Security Agreement” has the meaning set forth in Section 1.1(c) of this Agreement.

 

“Lead
Purchaser” has the meaning set forth in the first paragraph of this Agreement.

 

“Lien”
means a lien, charge, pledge, security interest, hypothecation, mortgage, encumbrance, right of first refusal, preemptive right
or other restriction.

 

“Material
Adverse Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities,
financial condition, property or results of operations of the Company and its Subsidiaries.

 

“Money
Laundering Laws” has the meaning set forth in Section 2.24 of this Agreement.

 

“Notes”
has the meaning set forth in Section 1.1(b) of this Agreement.

 

“OFAC”
has the meaning set forth in Section 2.23 of this Agreement.

 

“Organizational
Change” has the meaning set forth in Section 4.11 of this Agreement.

 

“Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

“Principal
Amount” has the meaning set forth in Section 1.1(b) of this Agreement.

 

“Purchaser”
and “Purchasers” has the meaning set forth in Section 1.1(b) of this Agreement.

 

“Purchaser
Party” has the meaning set forth in Section 4.7 of this Agreement.

 

    	4

    	 

    

 

“Required
Filings and Approvals” means collectively, (a) the filings required pursuant to Section 4.4, (b) the notice and/or
application(s) to each applicable Trading Market for the issuance and sale of the Notes and the listing of the Conversion Shares
for trading thereon in the time and manner required thereby and (c) the filing of a Form D with the Commission and such filings
as are required to be made under applicable state securities laws.

 

“Required
Minimum” means, as of any date (updated on a monthly basis), the maximum aggregate number of shares of Common Stock
then issuable pursuant to the Transaction Documents (including any Common Stock issuable upon conversion of Conversion Shares),
multiplied by 1.0.

 

“Right
of First Refusal and Co-Sale Agreement” means the Right of First Refusal and Co-Sale Agreement, dated as of November
15, 2019, among the Company and certain stockholders of the Company, as it may be amended and/or restated.

 

“SEC
Reports” has the meaning set forth in Section 2.8 of this Agreement.

 

“Securities”
means the Notes and the Conversion Shares.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Security
Agreement” has the meaning set forth in Section 1.1(c) of this Agreement.

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

 

“Subsidiary”
means any direct or indirect corporation, limited or general partnership, limited liability company, trust, estate, association,
joint venture or other business entity of which (a) more than 30% of (i) the outstanding capital stock having (in the absence
of contingencies) ordinary voting power to elect a majority of the board of directors or other managing body of such entity, (ii)
in the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or limited
liability company or (iii) in the case of a trust, estate, association, joint venture or other entity, the beneficial interest
in such trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or
indirectly through one or more intermediaries, by such entity, or (b) is under the actual control of the Company.

 

“Subsidiary
Guaranty” has the meaning set forth in Section 1.1(c) of this Agreement.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange, the OTC Bulletin Board, the OTCQX or OTCQB as maintained by OTC Markets, Inc.

 

“Transaction
Documents” means this Agreement, the Security Agreement, the Subsidiary Guaranty, the IP Security Agreement and the
Notes.

 

    	5

    	 

    

 

“Voting
Agreement” means the Amended and Restated Voting Agreement, dated as of November 15, 2019, among the Company and certain
stockholders of the Company, as it may be further amended and/or restated.

 

2.
Representations and Warranties of the Company . The Company represents and warrants to each Purchaser that the following
representations and warranties are true and complete as of the applicable Closing at which such Purchaser is acquiring Notes hereunder.
For purposes of these representations and warranties (other than those in Sections 2.1, 2.2, 2.3, and 2.4),
the term “Company” shall include any Subsidiaries of the Company, unless otherwise noted in this Agreement.

 

2.1.
Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly incorporated, validly
existing, and in good standing under the laws of the State of Nevada and has all requisite corporate power and authority to carry
on its business as presently conducted and as proposed to be conducted. The Company is duly qualified to transact business and
is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.

 

2.2.
Subsidiaries. Except as set forth on Schedule 2.2, the Company does not currently own or Control, nor has it ever
owned or Controlled, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited
liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership or
similar arrangement.

 

2.3.
Authorization. All corporate action required to be taken by the Board and the Company’s stockholders in order to
authorize the Company to enter into the Transaction Documents, and to issue the Notes at the Closing, has been taken or will be
taken prior to the Closing. All action on the part of the officers of the Company necessary for the execution and delivery of
the Transaction Documents, the performance of all obligations of the Company under the Transaction Documents to be performed as
of the Closing, and the issuance and delivery of the Securities to be issued at the Closing has been taken or will be taken prior
to the Closing other than in connection with the Required Filings and Approvals. The Transaction Documents, when executed and
delivered by the Company, will constitute valid and legally binding obligations of the Company, enforceable against the Company
in accordance with their respective terms.

 

2.4.
Valid Issuance. Assuming the accuracy of the representations of the Purchasers in Section 3 and subject to the filings
described in Section 2.5(a)(ii), the Securities will be issued in compliance with all applicable federal and state securities
laws. Subject to (i) Board approval of, and the filing of an amendment to, amendment and restatement of, or certificate of designation
with respect to, the Certificate in order to establish the series of preferred stock issuable upon conversion of the Notes, which
have been obtained or will be obtained in a timely manner and (ii) the valid election to convert the Note into Conversion Shares
in accordance with the terms of the Note, the Conversion Shares will be validly issued, fully paid, and nonassessable, and free
of restrictions on transfer other than restrictions on transfer under the Transaction Documents and the Certificate, applicable
federal and state securities laws, and Liens created by or imposed by the Purchasers. Based in part on the representations of
the Purchasers in Section 3, and subject to Section 2.5, the Conversion Shares issuable on conversion of the Notes
will be issued in compliance with all applicable federal and state securities laws.

 

    	6

    	 

    

 

2.5.
Governmental Consents and Filings; Compliance with Law and Other Instruments.

 

(a)
Assuming the accuracy of the representations made by the Purchasers in Section 3, no consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority
is required on the part of the Company in connection with the consummation of the transactions contemplated by the Transaction
Documents, except for (i) Board and stockholder approval of, and the filing of an amendment to, amendment and restatement of,
or certificate of designation with respect to, the Certificate in order to establish the series of any preferred stock issuable
upon conversion of the Notes, which have been obtained or will be obtained in a timely manner, and (ii) filings pursuant to Regulation
D of the Securities Act, and applicable state securities laws, which have been made or will be made in a timely manner.

 

(b)
The transactions contemplated by this Agreement and the other Transaction Documents will not require any authorization, consent,
approval, or waiver from, or notice to, any third person, except such as will have been validly completed or obtained prior to
the Closing other than the Required Filings and Approvals. The execution, delivery and performance of the Transaction Documents
and the consummation of the transactions contemplated by the Transaction Documents will not result in any such violation or be
in conflict with or constitute, with or without the passage of time and giving of notice, either (i) a default under any such
provision, instrument, judgment, order, writ, decree, contract or agreement or (ii) an event which results in the creation of
any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or non-renewal of any
material permit or license applicable to the Company.

 

2.6.
Financial Condition. The Company has delivered to each Purchaser its unaudited financial statements (including balance
sheet, income statement and statement of cash flows) for the fiscal year ended December 31, 2020 and for the 1-month period ended
January 31, 2021 (collectively, the “Financial Statements”). The Financial Statements fairly present in all
material respects the financial condition and operating results of the Company as of the dates, and for the periods, indicated
therein, subject to normal year-end audit adjustment (none of which would be material). Since December 31, 2020, the Company has
not suffered any Material Adverse Effect and no event has occurred, and no circumstance exists, that could reasonably be expected
to result in a Material Adverse Effect. The Company has no liabilities, obligations or commitments of any nature whatsoever, asserted
or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise except those
which are adequately reflected or reserved against in the most recent financial statements other than (i) those which are adequately
reflected or reserved against in the most recent Financial Statements, (ii) liabilities incurred in the ordinary course of business
subsequent to December 31, 2020; (iii) obligations under contracts and commitments incurred in the ordinary course of business
(other than as a result of a breach or default of the Company thereunder); and (iv) liabilities and obligations of a type or nature
not required under the U.S. generally accepted accounting principles to be reflected in the Financial Statements, which, in all
such cases, individually and in the aggregate would not have a Material Adverse Effect.

 

    	7

    	 

    

 

2.7.
Title to Assets. The Company has good and marketable title in fee simple to all real property owned by them and good and
marketable title in all personal property owned by them that is material to the business of the Company, in each case free and
clear of all Liens except for (a) Liens arising under, or permitted pursuant to, the Security Agreement, as the same may be amended
and/or restated from time to time, (b) Liens as do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and (c) Liens for the payment of federal, state or other
taxes, for which appropriate reserves have been made therefor in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved and the payment of which is neither delinquent nor subject to penalties.
Any real property and facilities held under lease by the Company are held by it under valid, subsisting and enforceable leases
with which the Company is in compliance.

 

2.8.
SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents, required to be filed
by the Company under Section 13 or 15(d) of the Exchange Act for the two years preceding the Effective Date (the foregoing materials,
in addition to all schedules, forms, statements and other documents filed with the Securities and Exchange Commission for the
two years preceding the Effective Date, including any amendments thereto, the exhibits thereto and documents incorporated by reference
therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange
Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act.

 

2.9.
Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial
advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. No Purchaser shall have any obligation with respect to any fees or with respect to any claims made
by or on behalf of other Persons for fees of a type contemplated in this Section 2.9 that may be due in connection with
the transactions contemplated by the Transaction Documents.

 

2.10.
Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section
3, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers
as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the
Trading Market.

 

    	8

    	 

    

 

2.11.
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended. The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act
of 1940, as amended.

 

2.12.
Listing and Maintenance Requirements. Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding
the Effective Date, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect
that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is required
to and has made current filings under Section 13 or 15(d) of the Exchange Act. The Common Stock is currently eligible for electronic
transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment
of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic
transfer.

 

2.13.
No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section
3, neither the Company, nor, to the Company’s knowledge, any of its Affiliates, nor any Person acting on its or their
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes
of the Securities Act which would require the registration of any such securities under the Securities Act.

 

2.14.
Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company (a) has made or filed all United States federal, state and local income and all foreign
income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (b) has paid all
taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations, and (c) has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know
of no basis for any such claim.

 

2.15.
No General Solicitation. Neither the Company nor, to the Company’s knowledge, any person acting on behalf of the
Company has offered or sold any of the Securities by any form of general solicitation or general advertising. The Company has
offered the Securities for sale only to the Purchasers and certain other “accredited investors” within the meaning
of Rule 501 under the Securities Act.

 

2.16.
Foreign Corrupt Practices. None of the Company or, the knowledge of the Company, any agent or other person acting on behalf
of the Company has: (a) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful
expenses related to foreign or domestic political activity, (b) made any unlawful payment to foreign or domestic government officials
or employees or to any foreign or domestic political parties or campaigns from corporate funds, (c) failed to disclose fully any
contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation
of law or (d) violated in any material respect any provision of FCPA. The Company further represents that it has maintained, and
has caused each of its Subsidiaries and affiliates to maintain, systems of internal controls (including, but not limited to, accounting
systems, purchasing systems and billing systems) and written policies to ensure compliance with the FCPA or any other applicable
anti-bribery or anti-corruption law, and to ensure that all books and records of the Company accurately and fairly reflect, in
reasonable detail, all transactions and dispositions of funds and assets. Neither the Company nor any of its officers, directors
or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related
to the FCPA or any other anti-corruption law.

 

    	9

    	 

    

 

2.17.
No Disagreements with Accountants and Lawyers; Outstanding SEC Comments. There are no disagreements of any kind presently
existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently
employed by the Company and the Company is or, immediately after the Initial Closing, will be current with respect to any fees
owed to its accountants which could affect the Company’s ability to perform any of its obligations under any of the Transaction
Documents. There are no unresolved comments or inquiries received by the Company or its Affiliates from the Commission which remain
unresolved as of the Effective Date.

 

2.18.
Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the
transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby
and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction
Documents and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities.
The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement and the other
Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company
and its representatives.

 

2.19.
Disqualification. No executive officer, member of the Board of Directors of the Company or, to the knowledge of the Company,
any shareholder of the Company beneficially owning more than 10% of the Company’s securities is currently subject to a Disqualifying
Event. For purposes of this Agreement, “Disqualifying Event” means any conviction, order, judgment, decree,
suspension, expulsion, event or other matter set out in Rule 506(d)(1)(i) through 506(d)(1)(viii) of Regulation D that is currently
in effect or which occurred within the periods set out in Rule 506(d)(1)(i) through (viii).

 

2.20.
Acknowledgment Regarding Each Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the
contrary notwithstanding, it is understood and acknowledged by the Company that: (a) none of the Purchasers has been asked by
the Company to agree, nor has any such Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of
the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for any
specified term, (b) past or future open market or other transactions by any Purchaser, specifically including, without limitation,
Short Sales or “derivative” transactions, before or after the closing of this or future private placement transactions,
may negatively impact the market price of the Company’s publicly-traded securities, (c) any Purchaser, and counter-parties
in “derivative” transactions to which any such Purchaser is a party, directly or indirectly, presently may have a
“short” position in the Common Stock and (d) each Purchaser shall not be deemed to have any affiliation with or control
over any arm’s length counter-party in any “derivative” transaction. The Company further understands and acknowledges
that (i) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding,
including, without limitation, during the periods that the value of the Securities are being determined, and (ii) such hedging
activities (if any) could reduce the value of the existing stockholders’ equity interests in the Company at and after the time
that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute
a breach of any of the Transaction Documents.

 

    	10

    	 

    

 

2.21.
Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (a) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Securities, (b) sold, bid for, purchased, or paid any compensation
for soliciting purchases of, any of the Securities, or (c) paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company, other than, in the case of clauses (b) and (c), compensation paid to
the Company’s placement agent, if any, in connection with the placement of the Securities.

 

2.22.
Insurance. The Company is insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company is engaged, including, but not limited to,
directors and officers insurance coverage in amounts customary in the businesses in which the Company and the Subsidiaries are
engaged. The Company does not have any reason to believe that it will not be able to renew its existing insurance coverage as
and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business
without a significant increase in cost.

 

2.23.
Office of Foreign Assets Control. None of the Company or, to the Company’s knowledge, any director, officer, agent, employee
or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of
the U.S. Treasury Department (“OFAC”).

 

2.24.
Money Laundering. The operations of the Company are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering
Laws”), and no Action by or before any court or governmental agency, authority or body or any arbitrator involving the
Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

    	11

    	 

    

 

2.25.
Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s articles of incorporation (or similar charter documents), any
certificates of designation adopted by the Company pursuant to its articles of incorporation or the laws of its state of incorporation
that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company’s issuance
of Securities and the Purchasers’ ownership of the Securities.

 

2.26.
Promotional Stock Activities. Neither the Company, nor any of its officers, directors, affiliates or agents, have engaged
in any stock promotional activity that could give rise to a complaint or inquiry by the Commission alleging (a) a violation of
the anti-fraud provisions of the U.S. federal securities laws, (b) violations of the anti-touting provisions of the U.S. federal
securities laws, (c) improper “gun-jumping” under applicable law, or (d) improper promotion of the Company or its
securities without adequate disclosure of compensation information.

 

2.27.
Disclosure. No representation or warranty of the Company contained in this Agreement, as qualified by the Schedules attached
hereto, and no certificate furnished or to be furnished to Purchasers at the Closing contains any untrue statement of a material
fact or, omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in
light of the circumstances under which they were made. All disclosures furnished in writing by or on behalf of the Company to
the Purchasers regarding the Company, its business and the transactions contemplated hereby, are true and correct and do not contain
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during
the twelve months preceding the Effective Date taken as a whole do not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made and when made, not misleading.

 

3.
Representations and Warranties of the Purchasers. Each Purchaser, severally and not jointly, represents and warrants to
the Company (with respect to itself only and not any other Purchaser), as of the Closing, that:

 

3.1.
Authorization. The Purchaser has full power and authority to enter into the Transaction Documents. The Transaction Documents
to which such Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations
of the Purchaser, enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights
generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies, or (b) to the extent the indemnification provisions contained in the Certificate may be limited by applicable federal
or state securities laws.

 

3.2.
Purchase Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation
to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser confirms, that the Securities to be
acquired by the Purchaser will be acquired for investment for the Purchaser’s own account and not with a view to the resale
or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation in,
or otherwise distributing the same. By executing this Agreement, the Purchaser further represents that the Purchaser does not
presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to
such Person or to any third Person, with respect to any of the Securities. The Purchaser has not been formed for the specific
purpose of acquiring the Securities.

 

    	12

    	 

    

 

3.3.
Restricted Securities. The Purchaser understands that the Securities have not been, and will not be, registered under the
Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among
other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed
in this Agreement. The Purchaser understands that the Securities are “restricted securities” under applicable U.S.
federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Securities indefinitely unless
they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such
registration and qualification requirements is available. The Purchaser acknowledges that the Company has no obligation to register
or qualify the Securities for resale except as set forth in the Investors’ Rights Agreement. The Purchaser further acknowledges
that if an exemption from registration or qualification is available, it may be conditioned on various requirements including,
but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company
which are outside of the Purchaser’s Control, and which the Company is under no obligation and may not be able to satisfy.

 

3.4.
No Public Market. The Purchaser understands that no public market now exists for the Securities, and that the Company has
made no assurances that a public market will ever exist for the Securities.

 

3.5.
Legends. The Purchaser understands that the Conversion Shares issued in respect of or exchange for the Notes, may bear
one or all of the following legends (or a substantially similar legend):

 

(a)
“THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND HAVE BEEN ACQUIRED
FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

 

(b)
Any legend set forth in, or required by, the other Transaction Documents and the Certificate.

 

(c)
Any legend required by the securities laws of any state to the extent such laws are applicable to the securities represented by
the certificate so legended.

 

    	13

    	 

    

 

3.6.
Accredited Investor. The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act.

 

3.7.
U.S. Investors. The Purchaser is a United States person (as defined by Section 7701(a)(30) of the Code).

 

3.8.
No General Solicitation. Neither the Purchaser nor any of its officers, managers, directors, employees, agents, members,
stockholders or partners has either, directly or indirectly, including through a broker or finder (a) engaged in any general solicitation,
or (b) published any advertisement, in connection with the offer and sale of the Securities.

 

3.9.
Residence. The office of the Purchaser in which its principal place of business is located is set forth on Schedule
I.

 

3.10.
Exculpation Among Purchasers. Each Purchaser acknowledges that it is not relying upon any Person, other than the Company
and its officers and directors, in making its investment or decision to invest in the Company. Each Purchaser agrees that no Purchaser
or the respective Controlling Persons, officers, directors, managers, partners, agents, or employees of any Purchaser shall be
liable to any other Purchaser for any action heretofore or hereafter taken or omitted to be taken by any of them in connection
with the purchase of the Securities. Each Purchaser, on its own behalf and on behalf of its Controlling Persons, officers, directors,
managers, partners, agents, or employees, hereby irrevocably covenants and agrees not to directly or indirectly assert any claims,
actions or causes of action whatsoever, in law or in equity and agrees not to commence, institute or cause to be commenced or
instituted, any proceeding of any kind against any other Purchaser or such Purchaser’s Controlling Persons, officers, directors,
managers, partners, agents, or employees, in connection with the purchase of the Securities hereunder.

 

4.
Other Agreements of the Parties.

 

4.1.
Acknowledgment of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the
outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges
that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Conversion Shares
pursuant to the Transaction Documents, are, except as otherwise set forth in the Transaction Documents, unconditional and absolute
and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any
claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership
of the other stockholders of the Company.

 

4.2.
Furnishing of Information. The Company represents and warrants to the Purchasers that the Company files reports with the
Commission pursuant to Section 13 or 15(d) of the Exchange Act. Until such time that no Purchaser owns Securities, the Company
covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file
(or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the
Company after the Effective Date pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements
of the Exchange Act.

 

    	14

    	 

    

 

4.3.
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities to
the Purchasers in a manner that would require the registration under the Securities Act of the sale of the Securities to the Purchasers.

 

4.4.
Securities Laws Disclosure; Publicity. The Company shall (a) promptly, and no later than 9:00 a.m. (New York City time)
on the third Trading Day immediately following the Effective Date, issue a press release disclosing the material terms of the
transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the
Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release,
the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates
on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and the
Lead Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated
hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement
without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of
the Lead Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed,
except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior
notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name
of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market,
without the prior written consent of such Purchaser, except: (i) as required by federal securities law in connection with the
filing of final Transaction Documents with the Commission and (ii) to the extent such disclosure is required by law or Trading
Market regulations, provided, however, that in each such case the, Company shall provide the Purchasers with prior notice of such
disclosure.

 

4.5.
Shareholder Rights Plan. The Company will not make or enforce any claim or, provide its consent to, any claim by any other
Person, that any Purchaser or group of Purchasers is an “Acquiring Person” under any control share acquisition,
business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement
in effect, or that any Purchaser or group of Purchasers could be deemed to trigger the provisions of any such plan or arrangement,
by virtue of receiving Securities under the Transaction Documents or any other agreement between the Company and the Purchasers.

 

    	15

    	 

    

 

4.6.
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither
it, nor any other Person acting on its behalf has provided or will provide any Purchaser or its agents or counsel with any information
that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser
shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The
Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company. To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser’s
consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company,
any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis
of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that
any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding
the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
transactions in securities of the Company.

 

4.7.
Indemnification of Purchasers. Subject to the provisions of this Section 4.7, the Company will indemnify and hold
each Purchaser and such Purchaser’s directors, officers, shareholders, members, managers, managing members, partners, employees
and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of
such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act
and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, managers, managing members, partners
or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts
paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party
may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements
made by the Company in this Agreement or in the other Transaction Documents, (b) any action instituted against the Purchaser Parties
in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such
Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based
upon a breach of such Purchaser Party’s representations, warranties or covenants under the Transaction Documents or any
agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party
of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence, willful
misconduct or malfeasance) or (c) any untrue statement or alleged untrue statement of a material fact contained in any registration
statement registering the sale or resale of the Securities, or related prospectus or prospectus supplement, or any information
incorporated by reference therein, or arising out of or based upon any omission or alleged omission to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. If any
action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such
Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume, pursue and maintain
the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have
the right to engage separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Purchaser Party except to the extent that (i) the engagement of such separate counsel
thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time
to assume, pursue and maintain such defense and to engage counsel or (iii) in such action there is, in the reasonable opinion
of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party,
in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel
for such Purchaser Party. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by
a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld, conditioned
or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser
Party’s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement
or in the other Transaction Documents. The indemnification required by this Section 4.7 shall be made by periodic payments
of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company
or others and any liabilities the Company may be subject to pursuant to law.

 

    	16

    	 

    

 

4.8.
Reservation and Listing of Securities.

 

(a)
From and after the Initial Closing, the Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance
pursuant to the Transaction Documents in such amount as may then be required to fulfill its obligations in full under the Transaction
Documents (including Common Stock issuable upon conversion of Conversion Shares).

 

(b)
If, on any date after the Initial Closing, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock
is less than the Required Minimum on such date, then the Board of Directors shall use commercially reasonable efforts to amend
the Company’s certificate or articles of incorporation to increase the number of authorized but unissued shares of Common
Stock to at least the Required Minimum at such time, as soon as possible and in any event not later than the 90th calendar day
after such date.

 

(c)
The Company shall, if applicable but only after the Initial Closing: (i) in the time and manner required by the principal Trading
Market, prepare and file with such Trading Market an additional shares listing application covering a number of shares of Common
Stock at least equal to the Required Minimum on the date of such application, (ii) take all steps necessary to cause such shares
of Common Stock to be approved for listing on such Trading Market as soon as possible thereafter, (iii) provide to each Purchaser
evidence of such listing, and (iv) maintain the listing of such Common Stock on any date at least equal to the Required Minimum
on such date on such Trading Market or another Trading Market.

 

4.9.
Form D; Blue Sky Filings. The Company shall timely file a Form D with respect to the Securities and shall provide a copy
thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine
is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to each applicable Purchaser at each
Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence
of such actions promptly upon request of any Purchaser.

 

    	17

    	 

    

 

4.10.
Transfer Agent. The Company covenants and agrees that it will at all times while the Securities remain outstanding maintain
a duly qualified independent transfer agent.

 

4.11.
Corporate Existence. So long as the Securities remain outstanding, the Company shall not directly or indirectly consummate
any merger, reorganization, restructuring, consolidation, sale of all or substantially all of the Company’s assets or any
similar transaction or related transactions, (each such transaction, an “Organizational Change”) unless the
Company provides the Purchasers with three (3) Trading Days written notice of such Organizational Change.

 

4.12.
Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered
or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless
the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision
constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended
for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or
as a group with respect to the purchase, disposition or voting of Securities or otherwise.

 

5.
Conditions to the Purchasers’ Obligations at each Closing. The obligations of each Purchaser to purchase the Notes
at their applicable Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless
otherwise waived by such Purchaser:

 

5.1.
Representations and Warranties True and Correct. The representations and warranties of the Company set forth in Section
2 shall be true and correct on and as of the date of such Closing.

 

5.2.
Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the
United States or of any state that are required in connection with the lawful issuance and sale of the Notes at the Closing shall
be obtained and effective as of such Closing.

 

5.3.
Exemption from Registration Requirements. The Notes to be issued at the applicable Closing shall be exempt from registration
requirements under the Securities Act and any applicable state securities laws.

 

5.4.
Consents. The Company shall have obtained and furnished to each Purchaser a copy of all consents and waivers required in
connection with the consummation of the transactions related to the purchase of the Notes at the applicable Closing.

 

5.5.
No Material Adverse Effect. The Company has not experienced a Material Adverse Effect as of the date of such Closing.

 

    	18

    	 

    

 

6.
Conditions to the Company’s Obligations at Each Closing. The obligations of the Company to sell Notes to the Purchasers
at the applicable Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless
otherwise waived by the Company:

 

6.1.
Representations and Warranties. The representations and warranties of each Purchaser contained in Section 3 that
is purchasing a Note at such Closing shall be true and correct in all respects as of such Closing.

 

6.2.
Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the
United States or of any state that are required in connection with the lawful issuance and sale of the Notes pursuant to this
Agreement shall be obtained and effective as of the applicable Closing.

 

7.
Agent.

 

7.1.
Appointment of Agent. Each Purchaser hereby constitutes and appoints the Lead Purchaser as their representative (the “Agent”)
and their true and lawful agents and attorney-in-fact, with full power and authority in each of their names and to act on behalf
of each of them in the absolute discretion of the Agent (i) with respect to the provisions of this Agreement and the other Transaction
Documents, and (ii) exercising all of the rights and remedies of the Purchasers under this Agreement and the other Transaction
Documents following an “Event of Default” under the Notes, an “Event of Default” under the Security Agreement
or any other default under any of the Transaction Documents. This appointment and grant of power and authority is coupled with
an interest and is in consideration of the mutual covenants made in this Agreement and is irrevocable and shall not be terminated
by any act of the Purchasers (other than the resignation of the Agent) or by operation of law. Each Purchaser consents to the
taking of any and all actions and the making of any decisions required or permitted to be taken or made by the Agent pursuant
to this Section 7.1. The Lead Purchaser may resign as Agent at any time by written notice to the Company and the other
Purchasers. Upon any such resignation, the Lead Purchaser shall use reasonable efforts to identify and appoint another Person
to replace it as Agent hereunder. If it is unable or otherwise does not appoint another Person to act as Agent, then the holders
of a majority in principal amount outstanding under the Notes shall fulfill the role of the Agent.

 

7.2.
Delegation of Duties. The Agent may execute its rights or authority under this Agreement by or through agents or attorneys-in-fact
and shall be entitled to advice of counsel concerning all matters pertaining to such rights and authority. The Agent shall not
be responsible for the negligence or misconduct of any agents or attorneys-in-fact selected by the Agent with reasonable care.

 

7.3.
Exculpatory Provisions. Neither the Agent nor any of its officers, directors, managers, employees, agents, partners, limited
partners, members, managers, officers, attorneys-in-fact, representatives, subsidiaries or affiliates shall be (a) liable for
any action lawfully taken or omitted to be taken by it or such Person in good faith under or in connection with this Agreement
or the other Transaction Documents, or (b) responsible in any manner to any of the Purchasers for any recitals, statements, representations
or warranties made by the Company or for any failure of the Company to perform its obligations under this Agreement or the other
Transaction Documents. The Agent shall not be under any obligation to ascertain or to inquire as to the observance or performance
of any of the agreements contained in, or conditions of, this Agreement or the other Transaction Documents, or to inspect the
books, records or properties of the Company.

 

7.4.
Reliance by the Agent. The Agent shall be entitled to rely, and shall be fully protected in relying, upon any note, writing,
resolution, notice, consent, certificate, affidavit, letter, cablegram, telegram, facsimile, electronic mail, statement, order
or other document, communication or correspondence believed by it to be genuine and correct and to have been signed, sent or made
by officers of the Company, public officials, other appropriate persons and upon advice and statements of legal counsel (including,
without limitation, counsel to the Company), independent accountants and other experts selected by the Agent. The Agent shall
be fully justified in failing or refusing to take any action under this Agreement and the other Transaction Documents unless they
shall first receive (but they are not required to obtain unless expressly stated elsewhere in this agreement) such advice or concurrence
of the Purchasers as they deem appropriate.

 

    	19

    	 

    

 

7.5.
Non-Reliance on Agent. Each Purchaser expressly acknowledges and agrees that neither Agent nor any of its respective officers,
directors, managers, employees, agents, partners, limited partners, members, managers, attorneys-in-fact, representatives, subsidiaries
or affiliates has made any representations or warranties to it and that no act by either Agent hereunder taken, including any
review of the affairs of the Company, shall be deemed to constitute any representation or warranty by Agent to any other Purchaser.
Each Purchaser further waives the fiduciary duty, if any, of the Agent with respect to its duties hereunder.

 

7.6.
Indemnification. Each of the Purchasers shall, on a proportionate basis in accordance with its or his ownership interest
in the Notes, indemnify and hold the Agent harmless from and against any and all losses, damages, expenses, liabilities, obligations,
penalties, actions, judgments, suits or disbursements (including reasonable counsel fees and expenses) which may be imposed on,
incurred or sustained by, or asserted against the Agent at any time in any way relating to or arising out of any action or omission
by the Agent in such capacity, except for those resulting from the Agent’s bad faith.

 

7.7.
Agent in its Individual Capacity. The Agent and its affiliates may make loans to and investments in and generally engage
in any kind of business with the Company as though they were not the Agent hereunder. With respect to its investments and any
indebtedness issued to it, the Agent shall have the same rights and powers under this Agreement and the other Transaction Documents
as any other Purchaser and may exercise the same to its own benefit, regardless of the impact on or to other Purchasers, as though
it were not Agent. The term “Purchaser” includes the Agent in its own capacity.

 

7.8.
No Action by Other Purchasers. No Purchaser other than the Agent shall pursue any remedies in respect of an “Event
of Default” under the Notes, an “Event of Default” under the Security Agreement or any other default under any
of the Transaction Documents, it being the intent of the Purchasers that any an action to enforce rights of the Purchasers under
any of the Transaction Documents be brought by the Agent as the representative of all Purchasers in a single action.

 

    	20

    	 

    

 

8.
Miscellaneous.

 

8.1.
Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company
and the Purchasers contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement
and the Closings, and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on
behalf of the parties hereto.

 

8.2.
Communications. Any public announcement or other disclosure to a third party regarding this Agreement or the investment
by any party hereto shall be subject to the prior written approval of each of the other parties to this Agreement, except as required
by Applicable Law, and except for disclosure by Lead Purchaser to its accountants, attorneys, and other advisors, or customary
disclosures by Lead Purchaser to its investors. Without limiting the foregoing, the Company shall not, without the prior written
approval of any Purchaser, (a) use in a press release, advertising, publicity, or otherwise, the name of such Purchaser or any
of its Affiliates or any trade name, trademark, trade device or simulation thereof owned by such Purchaser or its Affiliates,
(b) disclose the fact or nature of this investment by such Purchaser, or (c) represent, directly or indirectly, that any product
of service provided by the Company has been endorsed by such Purchaser or its Affiliates.

 

8.3.
Transfer; Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding
upon the respective successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties to this Agreement or their respective successors and permitted assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

8.4.
Governing Law. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and
construed in accordance with the laws of the State of Florida, without regard to its principles of conflicts of laws.

 

8.5.
Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts
of the State of Florida located in the County of Hillsborough and to the jurisdiction of the United States District Courts for
such county for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not
to commence any suit, action or other proceeding arising out of or based upon this Agreement except in such courts, and (c) hereby
waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim
that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment
or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding
is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

8.6.
Counterparts; Electronic Signatures. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. The exchange of copies of this Agreement
and of signature pages by electronic mail in “portable document format” (“.pdf”) form, or by any other
electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as
physical delivery of the paper document bearing an original signature

 

    	21

    	 

    

 

8.7.
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

8.8.
Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by facsimile if sent during normal
business hours of the recipient, and if not, then on the recipient’s next Business Day, (c) seven (7) days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) Business Day after deposit
(with full payment) with a nationally recognized overnight courier prior to such courier’s deadline for next Business Day
delivery, specifying next Business Day delivery, with written verification of receipt. All communications shall be sent to the
respective parties at their address(es) as set forth (x) for the Company, on the signature page, and (y) for the Purchasers, on
Schedule I, or to such facsimile number or address as subsequently modified by written notice given in accordance with
this Section 8.8.

 

8.9.
No Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or commission
in connection with this transaction. The Company agrees to indemnify and hold harmless each Purchaser from any liability for any
commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs
and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees
or representatives is responsible.

 

8.10.
Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party
incident to the negotiation, preparation, execution, delivery and performance of this Agreement, provided that the Company shall
pay all reasonable out-of-pocket legal, due diligence and administrative fees and expenses of counsel to the Lead Purchaser, with
respect to the Transaction Documents and the transactions contemplated thereby, regardless of whether such transactions are consummated.
The Purchasers will not be liable for any legal, due diligence, and administrative costs incurred by the Company regardless of
the amount of those costs.

 

8.11.
Attorneys’ Fees. If any action at law or in equity (including arbitration) is necessary to enforce or interpret the
terms of any of the Transaction Documents, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and
necessary disbursements in addition to any other relief to which such party may be entitled.

 

8.12.
Amendments and Waivers. Any term of this Agreement or the other Transaction Documents may be amended, terminated or waived
only with the written consent of the Company and the Lead Purchaser; provided that Schedule I may be updated by
the Company in accordance with Section 1 without any consent of the Purchasers. Any amendment or waiver effected in accordance
with this Section 8.12 shall be binding upon all of the Purchasers and each transferee of the Notes (or the Conversion
Shares issuable upon conversion or exercise thereof), each future holder of all such securities, and the Company. Any time any
provision of this Agreement allows for, contemplates or requires the consent of the Purchasers, such consent shall be deemed given
if Purchasers (or their assigns) holding at least a majority of the then aggregate principal amount of the Notes provide their
consent.

 

    	22

    	 

    

 

8.13.
Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision
of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law.

 

8.14.
No Waiver; Remedies Cumulative. No delay or omission on the part of any party in exercising any right, power or privilege
under this Agreement will operate as a waiver thereof, nor will any single or partial exercise of any right, power or privilege
hereunder or thereunder preclude other or further exercise thereof, or the exercise of any other right, power or privilege. The
rights and remedies provided in this Agreement are cumulative and are in addition to all rights or remedies that the Purchasers
or the Company otherwise may have in law or in equity or by statute or otherwise. Without limiting the generality of the foregoing,
nothing in this Agreement will be deemed to preclude or be in lieu of any right or remedy that the Purchaser or the Company may
have in law or in equity or by statute or otherwise against, in the case of the Purchaser, the Company, or any other person based
upon any fraud, and, in the case of the Company, the Purchaser or any other person based on fraud.

 

8.15.
Entire Agreement. This Agreement (including the Exhibits) and the other Transaction Documents constitute the full and entire
understanding and agreement between the parties with respect to the subject matter of this Agreement, and any other written or
oral agreements relating to the subject matter of this Agreement existing between the parties.

 

8.16.
Legal Counsel. Each party to this Agreement acknowledges that Hill, Ward & Henderson, P.A. (the “Firm”)
is serving as legal counsel to the Lead Purchaser. Each party to this Agreement further acknowledges that (a) the Firm has previously
served as counsel to the Company in unrelated matters, and (b) may continue to perform legal services for the Company in other
matters unrelated to the transactions described in this Agreement. Accordingly, each party to this Agreement hereby (i) acknowledges
that they have had an opportunity to ask for information relevant to this disclosure; and (ii) gives its informed consent to the
Firm’s representation of the Lead Purchaser in connection with this Agreement and the transactions contemplated hereby as
well as such other unrelated matters. Each Purchaser acknowledges that it has reviewed this Agreement and the related Transaction
Documents and has had the opportunity to engage separate counsel to review this Agreement the related Transaction Documents on
such Purchaser’s behalf.

 

8.17.
Acknowledgement. For avoidance of doubt, it is acknowledged that each Purchaser will be entitled to the benefit of all
adjustments in the number of shares of the Company’s capital stock as a result of any splits, reorganizations, combinations,
or other similar transactions affecting the Company’s capital stock underlying the Conversion Shares that occur prior to
the conversion of the Notes.

 

8.18.
Termination of Existing Investor Documents. Following the Closing, the Company shall use best efforts to obtain and furnish
to the Lead Purchaser evidence reasonably satisfactory to the Lead Purchaser that each of the Existing Investor Documents have
been terminated.

 

(Signature
Pages Follow)

 

    	23

    	 

    

 

H-CYTE,
INC.

SECURED
CONVERTIBLE NOTE PURCHASE AGREEMENT

COMPANY’S
SIGNATURE PAGE

 

The
undersigned has executed this Secured Convertible Note Purchase Agreement as of the date first written above.

 

	 	H-CYTE,
    INC.,
	 	a
    Nevada corporation
	 	 
	 	By:	 
	 	Name: 	Robert Greif
	 	Title: 	Chief Executive Officer
	 	 
	 	Address:
	 	 
	 	201
    E. Kennedy Blvd, Suite 700
	 	Tampa,
    FL 33602

 

    	 

    	 

    

 

H-CYTE,
INC.

SECURED
CONVERTIBLE NOTE PURCHASE AGREEMENT

LEAD
PURCHASER SIGNATURE PAGE

 

The
undersigned has executed this Secured Convertible Note Purchase Agreement as of the date first written above.

 

	 	LEAD
    purchaser:
	 	 
	 	FWHC
    BRIDGE, LLC
	 	 
	 	By:	 
	 	Name:	 Todd R. Wagner
	 	Title:	 Manager

 

    	 

    	 

    

 

H-CYTE,
INC.

SECURED
CONVERTIBLE NOTE PURCHASE AGREEMENT

ADDITIONAL
PURCHASER SIGNATURE PAGE

 

The
undersigned has executed this Secured Convertible Note Purchase Agreement as of __________________________.

 

	 	PURCHASER:
	 	 
	 	 
	 	(Entity
    name, if applicable)
	 	 
	 	 
	 	(Print
    name)
	 	 
	 	 
	 	(Signature)
	 	 
	 	 
	 	(Print
    name of signatory, if signing for an entity)
	 	 
	 	 
	 	(Print
    title of signatory, if signing for an entity)

 

    	 

    	 

    

 

SCHEDULE
I

 

PURCHASERS

 

	Purchaser	 	Purchase Price/Principal Amount of Note	 
	FWHC Bridge, LLC
 334 East Lake Road, Suite 176
 Palm Harbor, FL 34685 
  
Attention: Leslie McMahon	 	$	1,500,000	 
	CFRS Investments	 	 	300,000	 
	CTS Equities, L.P.	 	$	500,000	 
	DB-BZ, LLC	 	$	250,000	 
	FWHC Bridge Friends, LLC	 	$	25,000	 
	 	 	 	 	 
	Total:	 	$	2,575,000	 

 

    	 

    	 

    

 

Schedule
2.2

 

SUBSIDIARIES

 

The
following entities are Subsidiaries of the Company:

 

	 	1.	Medovex Corp.
	 	2.	H-Cyte Management, LLC f/k/a Blue Zone Health
    Management, LLC
	 	3.	Lung Institute Tampa, LLC f/k/a Blue Zone Lung
    Tampa, LLC
	 	4.	Cognitive Health Institute Tampa, LLC

 

    	 

    	 

    

 

EXHIBIT
A

 

FORM
OF NOTE

 

(Attached)

 

    	 

    	 

    

 

EXHIBIT
B

 

FORM
OF SECURITY AGREEMENT

 

(Attached)

 

    	 

    	 

    

 

EXHIBIT
C

 

FORM
OF SUBSIDIARY GUARANTY

 

(Attached)

 

    	 

    	 

    

 

EXHIBIT
D

 

FORM
OF IP SECURITY AGREEMENT

 

(Attached)ex_239478.htm

Exhibit 10.1

 

 

425 Eagle Rock Ave, Suite 403

Roseland, NJ 07068

April 6, 2021

 

Leonard Osser

Camlet Court

Roseland, New Jersey 07068

 

Re: Succession Agreement

 

Dear Leonard,

 

As part of the Succession Plan of Milestone Scientific Inc., a Delaware corporation (the “Company”), you have agreed with the Company to restructure certain of your existing agreements with the Company and to provide for additional and broader executive support, and at such time as you elect to step down as the Company’s Interim Chief Executive Officer to become the Vice Chairman of the Company’s Board of Directors (the “Board”).

 

	
			1.

				
			Existing Agreements.

			

 

	 	
			(a)

				
			For the avoidance of doubt, each of the following agreements (each an “Existing Agreement” and collectively the “Existing Agreements”) is intended to survive in accordance with its terms, except as expressly provided in paragraphs 1(b), (c) and (d) below:

			

 

	 	
			(i)

				
			the Employment Agreement dated September 1, 2009, as amended, between you and the Company (the “2009 Agreement”);

			

 

	 	
			(ii)

				
			the Employment Agreement dated as of July 10, 2017 between you and the Company, consolidating into one agreement provisions of that certain Employment Agreement dated January 1, 2008 and the amendment thereto dated March 6, 2013 (the “2008 Agreement”), pursuant to which upon you stepping down as Chief Executive Officer of the Company the Company agreed to employ you as Managing Director, China Operations of the Company (the “China Operations Agreement”); and

			

 

	 	
			(iii)

				
			the Consulting Agreement dated as of July 10, 2017 (the “Consulting Agreement”) between the Company and U.S. Asian Consulting Group, LLC, a company of which you are a principal.

			

 

 

 

 

	 	
			(b)

				
			With respect to the China Operations Agreement, the following shall be applicable:

			

 

	 	
			(i)

				
			Compensation. Your compensation payable under the China Operations Agreement shall be reduced from $300,000 per annum to $200,000 per annum, consisting of $100,000 in cash payable in accordance with the Company’s usual executive compensation arrangements and $100,000 in the Company’s common stock valued in accordance with and subject to the other terms of the China Operations Agreement.

			

 

	 	
			(ii)

				
			Benefits. You will continue to receive all benefits to be provided by the Company to you pursuant to the China Operations Agreement. Without limiting the foregoing, such benefits shall include the following, subject to the terms of the China Operations Agreement:

			

 

	 	
			(A)

				
			such major medical, and family health coverage benefits and long-term disability group plan coverage generally available to the Company’s officers. To the extent you qualify, you may participate in, or benefit under, any employee benefit plan, arrangement or perquisite made available by the Company to its key executives;

			

 

	 	
			(B)

				
			ordinary and necessary business related expenses as shall be incurred by you in the course of the performance of your duties under this agreement; and

			

 

	 	
			(C)

				
			a monthly car allowance in the amount of $1,200.

			

 

	 	
			(c)

				
			With respect to the Consulting Agreement, the following shall be applicable:

			

 

	 	
			(i)

				
			Compensation. Your compensation payable under the Consulting Agreement shall be changed from $100,000 per annum to $200,000 per annum, consisting of $100,000 in cash payable monthly in arrears, on the last day of each month, and $100,000 in the Company’s common stock, which shares were formerly payable under the China Operations Agreement. The provisions of the China Operations Agreement with respect to the issuance and deferral of the shares issuable pursuant to such agreement shall continue to be applicable to the shares issuable pursuant to the Consulting Agreement, mutatis mutandis.

			

 

 

 

 

	 	
			(d)

				
			General.

			

 

	 	
			(i)

				
			Deferral. Notwithstanding the termination of the 2008 Agreement and the 2009 Agreement, the change in status set forth above or the change of 100,000 shares of stock being issued under the China Operations Agreement to being issued under the Consulting Agreement, you shall be entitled (A) at the expiration of the Consulting Agreement for any reason, to all compensatory and other benefits (including shares of Company stock) earned by you under such agreement prior to the termination thereof, and (B) at the expiration of the 2009 Agreement term for any reason to all compensatory and other benefits (including shares of Company stock) earned by you under (x) the 2008 Agreement prior to the 2009 Agreement termination date, (y) the 2009 Agreement prior to the 2009 Agreement termination date, and (z) any other contract, plan or agreement providing for the payment of benefits or compensation upon, following or in connection with a termination of your employment or retention; provided, however, that if you are a “specified employee” of the Company within the meaning of Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”) (or any successor provision), no payment under this Section 1(b)(iv) in connection with your termination of employment (other than a payment of salary through the date of such termination, and payments on account of termination of employment or retention by reason of death) shall be made until the date which is six (6) months after the date of the termination of your retention (or, if earlier, the date of your death); provided further, if the Company determines based upon written advice of counsel that any such payment if made during the calendar year that includes the termination date would not be deductible in whole or in part by reason of Code §162(m), such payment shall be made on January 2 of the following calendar year (or such later date as may be required under the preceding proviso if you are a “specified employee”).

			

 

	 	
			(ii)

				
			Certain Fees. At such time as you step down as the Company’s Interim Chief Executive Officer and become the Vice Chairman of the Company’s Board of Directors, you will be entitled to director’s fees as a part-time employee on the same basis as non-employee directors.

			

 

	 	
			(iii)

				
			Full Force and Effect. Except as set forth above, the Existing Agreements shall remain in full force and effect.

			

 

	
			2.

				
			Board Responsibilities. As you are currently a member of the Board, your responsibilities as a member of the Board will continue. As you know, your responsibilities as a member of the Board include the following:

			

 

	 	
			●

				
			Generally: You shall have all responsibilities of a Director of the Company imposed by Delaware or applicable law, and to the extent not inconsistent with such laws, the Certificate of Incorporation and Bylaws of the Company, as each may be amended from time to time;

			

 

	 	
			●

				
			Attendance: Use best efforts to attend scheduled meetings of the Board;

			

 

	 	
			●

				
			Act as a Fiduciary: Represent the stockholders and the interests of the Company as a fiduciary;

			

 

	 	
			●

				
			Participation: Participate as a full voting member of the Board in setting overall objectives, approving plans and programs of operation, formulating general policies, offering advice and counsel, serving on Board Committees, and reviewing management performance;

			

 

 

 

 

	 	
			●

				
			Integrity: Uphold high standards of integrity and probity and extend your support in instilling the appropriate culture, values and behaviors in the boardroom and beyond; and

			

 

	 	
			●

				
			Growth: Contribute to the growth of the Company in a meaningful way.

			

 

	
			3.

				
			Committee(s). The Board may in the future, with your approval, appoint you to a committee. In such event, the then current charter for such committee will be furnished to you.

			

 

	
			4.

				
			Consulting Services. From and after such time as you elect to step down as the Interim Chief Executive Officer of the Company, in addition to serving as Vice Chairman of the Board, you shall provide general consulting services to the Company or to the Company’s subsidiaries and affiliated companies from time to time when reasonably requested by the Chief Executive Officer of the Company and at times reasonably convenient to you, subject to your other commitments (the “General Consulting Services”). The sole compensation to which you will be entitled in respect of the General Consulting Services will be the Stock Options referred to in paragraph 5. The Company shall seek to give you reasonable advance notice of any in-person or telephone meetings requested of you hereunder. You shall not have a minimum time commitment for such services, it being understood that your commitment is to be available for consultation from time to time as aforesaid, but not to be required to provide any specific service at any specific time. The Company acknowledges that, subject to the limitations set forth in this agreement, you shall be free to engage in other business related activities as an employee or otherwise for other persons or entities.

			

 

	
			5.

				
			Stock Options. In connection with your acceptance of the position of Vice Chairman of the Board and in consideration of your services as a member of the Board and agreement to provide the General Consulting Services during the term of this agreement, you will be granted options to purchase 2,000,000 shares of the Company’s common stock (the “Stock Options”), at an exercise price equal to the fair market value of the common stock on the date of grant. The Stock Options will vest annually over five (5) years, beginning on the first anniversary of such date as you elect to step down as the Interim Chief Executive Officer of the Company, or ten years from the date of grant, whichever shall end first, in accordance with the standard option agreement approved by the Board. Vesting will, of course, depend on you continuing to provide the General Consulting Services. If you resign or you are removed from the Board, vesting of your Stock Options will cease, unless you continue to provide the General Consulting Services. If you cease providing General Consulting Services, but continue on the Board, vesting of the Stock Options will cease. If your services are terminated by the Company for Cause (as defined below), your unexercised Stock Options will be forfeited. The Stock Options will be non-statutory stock options and will be subject to the terms of the Company’s 2011 Equity Compensation Plan (f/k/a Milestone Scientific 2011 Stock Option Plan), to the extent of available shares, and the Company’s 2020 Equity Incentive Plan (collectively, the “Plan”) and, except as set forth in this paragraph, the Company’s standard stock option agreement approved by the Board, to be entered into by you and the Company. The Company reserves the right to modify or discontinue the Plan in the future. Please consult the Plan for further information. The grant of the Stock Options is contingent upon you signing and delivering to the Company customary grant documents under the Plan (consistent with the terms outlined herein).

			

 

 

 

 

	
			6.

				
			Change of Control. In the case of a Change of Control of the Company, if a Board seat in the surviving company is not offered to you, or if you are required to resign your position as a Director as a condition of a Change of Control, or removed from your position as a Director in connection with a Change of Control, vesting would be accelerated for 100 percent for any unvested Stock Options then held by you. A “Change of Control” has the meaning set forth under the Plan.

			

 

	
			7.

				
			Reimbursement; Indemnification. The Company will reimburse you for all reasonable travel expenses that you incur in connection with your attendance at meetings of the Board or in connection with other services provided to the Company, in accordance with the Company’s expense reimbursement policy as in effect from time to time. Nothing contained in this agreement is intended to affect any reimbursement to which you are or may become entitled under an Existing Agreement.

			

 

	
			8.

				
			Indemnification. You will receive indemnification as a Director of the Company to the maximum extent extended to Directors of the Company generally, as set forth in the Company’s certificate of incorporation, bylaws, an indemnification agreement between the Company and you (which will be provided to you upon the Effective Date (defined below)) and any director and officer insurance the Company may have and maintain from time to time.

			

 

	
			9.

				
			Conflicts. It is accepted and acknowledged that you may have business interests other than those of the Company and will declare any conflicts that are apparent at present. In the event that you become aware of any potential conflict of interest, you agree to disclose the same to the Chairman of the Board of the Company and the Company Secretary as soon as you become aware of the same. In accepting this offer, you are representing to us that (i) neither this letter nor the performance of services hereunder will conflict with or violate any obligation that you owe to, or any right of, any third party, including, without limitation, any obligations to or rights of any current or prior employer of yours or other company you work or have worked with (e.g., a “no-moonlighting” clause, exclusive services agreement, non-compete agreement or other invention assignment agreement), and you do not know of any conflict which would restrict your service on the Board, and (ii) you will not provide the Company with any documents, records, or other confidential information belonging to any other party.

			

 

	
			10.

				
			Effective Date. If you accept these terms, the Stock Options will be granted upon Compensation Committee action. However, as noted above, the Stock Options will not begin to vest, you will not become Vice Chairman of the Board and the General Consulting Services will not begin to be performed until such time as you elect to step down as Interim Chief Executive Officer of the Company.

			

 

 

 

 

	
			11.

				
			Duration of Appointment; Time Commitment. The Company expects your commitment to the Company as Vice Chairman will be for at least five (5) years from the date you become Vice Chairman. Your time commitment would be for at least four (4) Board meetings a year. Recently all meetings have been, and for the foreseeable future all meetings are expected to be, remote, via audio/video conference facility, as the case may be. When in-person meetings resume, they will be held at or in the vicinity of the offices of the Company in New Jersey. You will be expected to devote appropriate preparation time ahead of each meeting. In addition to the above, depending on business exigencies, additional meetings may be convened. Moreover, you may be nominated to one or more Committees of the Board, from time to time. While the Company would seek your convenience for availability before fixing dates for such meetings, this will depend on the overall convenience of a majority of Directors or committee members, as the case may be. Also, we will seek your guidance, suggestions and support, whenever we need your help.

			

 

	
			12.

				
			Non-Disclosure; Non-Competition.

			

 

	 	
			(a)

				
			You agree not to use or disclose, either during the term of this agreement or at any time thereafter, except with the prior written consent of the Board of Directors, any trade secrets, proprietary information, or other information that the Company reasonably considers confidential relating to processes, suppliers (including but not limited to a list or lists of suppliers), customers (including but not limited to a list or lists of customers), compositions, improvements, inventions, operations, processing, marketing, distributing, selling, cost and pricing data, or master files utilized by the Company, not presently generally known to the public, and which is, obtained or acquired by you while affiliated with the Company.

			

 

	 	
			(b)

				
			During the term of this agreement and for a period of two years thereafter, you shall not, directly or indirectly, in any manner, provide services to any other person or entity that provides products or services functionally similar to or competing with a product or service of or reasonably contemplated to be provided by the Company or engage in any business which competes with any business conducted by the Company (including any subsidiary) and will not directly or indirectly own, manage, operate, join, control or participate in the ownership, management, operation or control of, or be employed by or connected in any manner with any corporation, firm or business that is so engaged (provided, however, that nothing herein shall prohibit you from owning not more than three percent (3%) of the outstanding stock of any publicly held corporation).

			

 

	 	
			(c)

				
			During the term of this agreement and for two (2) years thereafter, you shall not take any action which might divert from the Company any opportunity learned about by you during your affiliation with the Company which would be within the scope of any of the businesses then engaged in or planned to be engaged in by the Company. The parties acknowledge that currently the Company’s business is the delivery of anesthetics and other medicaments through computer controlled systems.

			

 

	
			13.

				
			Intentionally Omitted. 

			

 

 

 

 

	
			14.

				
			No Solicitation of Employees, Consultants, Contractors or Customers. You agree that for the period of your service as a member of the Board, and for the period of two (2) years after the later of (1) the date your service to the Company ends for any reason, including but not limited to voluntary termination by you or removal by the Company, or (2) the date a court of competent jurisdiction enters an order enforcing this provision, you will not, either directly or through others, (i) solicit, entice, persuade or induce any individual or entity who or which is then, or has been within the preceding six-month period, an employee or independent consultant, advisor, independent contractor, representative or other agent of the Company to end his or her relationship with the Company or a subsidiary; or (ii) any consultant, contractor, customer or potential customer of the Company with whom you had contact or whose identity you learned as a result of your service to the Company or a subsidiary to diminish or materially alter its relationship with the Company or a subsidiary, and you shall not approach any such employee, consultant contractor, customer or potential customer for any such purpose or authorize or knowingly approve the taking of any such actions by any other individual or entity. The term “affiliate” shall mean any person or entity that directly, or indirectly, through one or more intermediaries, is controlled or is controlled by, or is under common control of the Company.

			

 

	
			15.

				
			Remedy. Since a breach of the provisions of paragraphs 12 and 14 of this letter could not adequately be compensated by money damages, the Company shall be entitled, in addition to any other right and remedy available to it, to an injunction restraining such breach or a threatened breach, and in either case no bond or other security shall be required in connection therewith. You agree that the provisions of this letter are necessary and reasonable to protect the Company in the conduct of its business.

			

 

	
			16.

				
			Termination. Notwithstanding, anything contained herein to the contrary, the Company and you agree that the Company may terminate this agreement for Cause and, in such event, all unexercised Stock Options, whether or not then vested, shall immediately be forfeited. The Company may terminate this agreement for Cause. The Company shall have no right of termination of the General Consulting Services other than for “Cause.” As used herein, the term “Cause” shall have the meaning set forth in the Plan; provided, that in the event of your willful and continued failure to substantially perform General Consulting Services, the Company will give you written notice of such failure, and the opportunity to cure such failure (if capable of being cured) within thirty (30) days following written notice thereof from the Company.

			

 

	
			17.

				
			Independent Contractor. You agree that all services will be rendered by you as an independent contractor. You are not and shall not be considered as an employee or partner of the Company. You shall have no right to receive any benefits, including but not limited to, health and accident insurance, life insurance, paid sick leave and/or paid vacation time, except as provided under paragraph 1(b)(ii) or any of the Existing Agreements. You agree to pay all taxes and other financial obligations resulting from the consideration paid by the Company to you under this agreement, including but not limited to self-employment taxes. You shall indemnify the Company in the event the Company is required to pay any such taxes on behalf of you. In the event any law, rule, regulations or other legal obligation requires the Company to withhold and pay to a governmental entity any portion of the compensation payable by the Company to you, then the Company shall be permitted to deduct and withhold such amount from the compensation payable to you under this agreement and thereafter the Company shall pay such withheld amount to the proper governmental entity in a timely manner.

			

 

 

 

 

	
			18.

				
			Disclosure. You acknowledge and agree that Company may publicly disclose that you are or were a member of Company’s Board.

			

 

	
			19.

				
			Enforcement. This agreement shall inure to the benefit of and be enforceable by your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If any amount is due to you pursuant to this agreement at or following the time of your death, any such amount shall be paid in accordance with the terms of this agreement to your estate. The Company shall require any purchaser or purchasers of the Company or any purchaser or purchasers of substantially all of the business or assets of the Company, by agreement in form and substance satisfactory to you, to assume and agree to perform this agreement in the same manner and to the same extent that the Company would be required to perform it if no such purchase had taken place. As used in this agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business or assets which executes and delivers the agreement provided for in this paragraph 19 or which otherwise becomes bound by all the terms and provisions of this agreement by operation of law.

			

 

	
			20.

				
			Severability of Covenants. In the event that any provision of this agreement, including any sentence, clause or part hereof, shall be deemed contrary to law or invalid or unenforceable in any respect by a court of competent jurisdiction, the remaining provisions shall not be affected, but shall remain in full force and effect and any invalid and enforceable provisions shall be deemed, without further action on the part of the undersigned, modified, amended and limited solely to the extent necessary to render the same valid and enforceable.

			

 

	
			21.

				
			Governing Law. This letter shall be construed, interpreted and enforced in accordance with the laws of the State of Delaware, without regard to conflict of laws.

			

 

	
			22.

				
			Counterparts. This agreement may be executed in one or more counterparts, each of which shall comprise an original and all of which shall be considered a single agreement.

			

 

	
			23.

				
			Headings. Headings and subheadings are for ease of reference only and shall not be considered to be a part of this agreement.

			

 

This letter sets forth the entire compensation you will receive for the General Consulting Services. Nothing in this letter should be construed as an offer of employment.

 

We hope that you find the foregoing terms acceptable and we look forward to your acceptance of our offer and to your election to the Board of the Company as Vice Chairman. If the terms are agreeable, please sign and date a copy of this letter indicating your acceptance, and return it to me.

 

 

 

 

Leonard, I look forward to having you on the Board as Vice Chairman and trust your relationship with the Company will continue to be challenging and exciting.

 

	 	
			Sincerely,

			 

			/s/ Leslie Bernhard                          

			Name: Leslie Bernhard

			Title: Chairman of the Board

			 

			Acknowledged and Agreed to:

			 

			 

			 

			/s/ Leonard Osser                             

			Name: Leonard Osser

			 

			Dated: April 6, 2021

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]